• Julie Rode, Julie Pique, Adil Maarouf, Xavier Ayrignac, Bertrand Bourre, Jonathan Ciron, Mikael Cohen, Nicolas Collongues, Romain Deschamps, Elisabeth Maillart, Alexis Montcuquet, Caroline Papeix, Aurelie Ruet, Sandrine Wiertlewski, Helene Zephir, Romain Marignier, and Bertrand Audoin.
• Service de neurologie, Hôpital de la Timone, APHM, Marseille, France julie.rode@ap-hm.fr.
• J. Neurol. Neurosurg. Psychiatr. 2023 Apr 1; 94 (4): 309313309-313.

BackgroundTo characterise the response to treatment of inaugural optic neuritis (ON) in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).MethodsWe searched the French MOGAD database for adults with inaugural ON with a detailed report of acute treatment modalities and measures of high-contrast best-corrected visual acuity (BCVA) at nadir and after 3 months. Predictors of visual outcomes were assessed by multivariable analysis.ResultsAmong 245 patients with at least one episode of ON, 82 fulfilled all criteria, and data on the peripapillary retinal nerve fibre layer (pRNFL) were available for 44. All patients received methylprednisolone (MP), combined with plasma exchange in 18. After 3 months, 75 of 82 (91%) patients retained full BCVA recovery, and median (range) pRNFL of the affected eye was 72 µm (40-102). Failure to regain 0.0 logarithmic minimum angle of resolution vision (Snellen 20/20) at 3 months was associated with time to first MP treatment ≥10 days (OR 16, 95% CI 1.14 to 213, p=0.01). pRNFL thickness after 3 months was related to better BCVA at nadir and time to first MP treatment <10 days (r2=19%, p=0.004 and r2=11%, p=0.03, respectively).ConclusionsTime to MP affects functional but also structural visual outcomes of ON in MOGAD.© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

14 keywords...

hide…